Genotoxicity of Streptozotocin

Mutation Research - Reviews in Mutation Research

Volumn 512, Issue 2-3, 2002, Pages 121-134

  Bolzán, Alejandro D ^a   Bianchi, Martha S ^a  

^a Instituto Multidisciplinario de Biologia Celular   (Argentina)

Author keywords

Genotoxicity; Streptozocin; Streptozotocin

Indexed keywords

ANTIOXIDANT; BARBITAL; CYCLOSPORIN A; DOXORUBICIN; FLUOROURACIL; FREE RADICAL; METAL CHELATE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROCARBAZINE; SEMUSTINE; STREPTOZOCIN; TIOGUANINE; VINCRISTINE;

AMES TEST; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASSAY; BACTERIUM MUTANT; CARCINOGENIC ACTIVITY; CELL DEATH; CHINESE HAMSTER; CHROMOSOME ABERRATION; CHROMOSOME DAMAGE; DIABETES MELLITUS; DNA ADDUCT; DNA DAMAGE; DNA METHYLATION; DNA STRAND BREAKAGE; DROSOPHILA MELANOGASTER; DRUG INDUCED DISEASE; EUKARYOTIC CELL; GASTROINTESTINAL CARCINOMA; GENOTOXICITY; HUMAN; KIDNEY TUMOR; LIVER TUMOR; MICRONUCLEUS; MUTAGENIC ACTIVITY; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS TUMOR; PRIORITY JOURNAL; REVIEW; SALMONELLA TYPHIMURIUM; SISTER CHROMATID EXCHANGE; STREPTOMYCES; STREPTOMYCES ACHROMOGENES; TRANSGENIC MOUSE; UNSCHEDULED DNA SYNTHESIS;

ANIMALIA; BACTERIA (MICROORGANISMS); EUKARYOTA; STREPTOMYCES; STREPTOMYCES ACHROMOGENES;

EID: 0036898999     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(02)00044-3     Document Type: Review

References (136)

1. Lewis C., Barbiers A.R. Streptozotocin, a new antibiotic. In vitro and in vivo evaluation. Antibiot. Ann. 7:1959/1960;247-254.
2. Vavra J.J., Deboer C., Dietz A., Hanka L.J., Sokolski W.T. Streptozotocin, a new antibacterial antibiotic. Antibiot. Ann. 7:1959/1960;230-235.
3. Herr R.R., Jahnke A.D., Argoudelis A.D. The structure of Streptozotocin. J. Am. Chem. Soc. 89:1967;4808-4809.
4. Hardegger E., Meier A., Stoos A. A preparative synthesis of Streptozotocin. Helv. Chim. Acta. 52:1969;2555-2560.
5. Hessler E.J., Jahnke H.K. Improved synthesis of Streptozotocin. J. Org. Chem. 35:1970;245-246.
6. A.W. Prestayko, S.T. Crooke, L.H. Baker, S.K. Carter, P.S. Schein (Eds.), Nitrosoureas: Current Status and New Developments, Academic Press, London, 1981.
7. M. Colvin, B.A. Chabner, Alkylating Agents, in: B.A. Chabner, J.M. Collins (Eds.), Cancer Chemotherapy Principies and Practice, J.B. Lippincott, Philadelphia, 1990, pp. 276-313.
8. McConnick J.E., McElhinney R.S. Nitrosoureas from chemist to physician: classification and recent approaches to drug design. Eur. J. Cancer. 26:1990;207-221.
9. Newlands E.S., Blackledge G.P., Slack J.A., Rustin G.J.S., Srnith D.B., Stuart N.S.A., Quarterman C.P., Hoffman R., Stevens M.F.G., Brampton M.H., Gibson A.C. Phase I trial of temozolornide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer. 65:1992;287-291.
10. Dolan M.E. Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents. Adv. Drug Del. Rev. 26:1997;105-118.
11. Day III R.S., Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Libiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D. Defective repair of alkylated DNA by human tumor and SV-40 transformed human cell strains. Nature. 288:1980;724-727.
12. Goldmaker V.S., Cuzich R.A., Thilly W.G. Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation of methylnitrosourea and N-methyl-N′-nitro-N-nitrosoguanidine. J. Biol. Chem. 261:1986;12462-12471.
13. Goth-Goldstein R., Hughes M. Characterization of a CHO variant in respect to alkylating agent-induced biological effects and DNA repair. Mutat. Res. 184:1987;139-146.
14. Tokuda K., Bodell W.J. Cytotoxicity and induction of sister chromatid exchanges in human and rodent brain tumor cells treated with alkylating chemotherapeutic agents. Cancer Res. 48:1988;3100-3105.
15. 6-alkylguanine-DNA-alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 50:1990;6119-6129.
16. Capucci M.S., Hoffmann M.E., Natarajan A.T. Streptozotocin-induced genotoxic effects in Chinese hamster cells: the resistant phenotype of V79 cells. Mutat. Res. 347:1995a;79-85.
17. Boivin J.F., Hutchison G.B., Zauber A.G., Bemstein L., Davis F.G., Michel R.P., Zanke B., Tan C.T., Fuller L.M., Mauch P. Incidence of second cancers in patients treated for Hodgkin's disease. J. Natl. Cancer Inst. 87:1995;732-741.
18. Smith M.A., McCaffrey R.P., Karp J.E. The secondary leukernias: cha1lenges and research directions. J. Natl. Cancer Inst. 88:1996;407-418.
19. Togni P., Sessa C., Varini M., Cavalli F. The combination of methyl-CCNU, vincristine, 5-fluorouracil and Streptozotocin in the treatment of advanced colo-rectal adenocarcinoma. Schweiz Med. Wochenschr. 112:1982;930-933.
20. Weltz M.D., Perry D.J., Blom J., Butler W.M. Methyl-CCNU, 5-fluoouracil, vincristine, and Streptozotocin in metastatic colo-rectal carcinoma. J. Clin. Oncol. 1:1983;135-137.
21. Gastrointestinal Tumor Study Group. Phase II study of methyl-CCNU, vincristine, 5-fluorouracil, and Streptozotocin in advanced colorectal cancer by the Gastrointestinal Tumor Study Group, J. Clin. Oncol. 2 (1984) 770-773.
22. Clamon G., Riggs C., Stegink L., Traves M. Phase 2 trial of Streptozotocin by continuous infusion for metastatic colorectal carcinoma. Cancer Drug Deliv. 4:1987;43-46.
23. Ridolfi R., Amaducci L., Derni S., Fabbri L., Innocenti M.P., Vignutelli P. Chemotherapy with 5-fluorouracil and Streptozotocin in carcinoid tumors of gastrointestinal origin: experiences with 13 patients. J. Chemother. 3:1991;328-331.
24. R.T. Dorr, W.L. Fritz, Streptozotocin, in: Cancer Chemotherapy Handbook, Elsevier, New York, 1980, pp. 632-640.
25. Chow S.N., Seear M., Anderson R., Magee F. Multiple pulmonary chemodectomas in a child: results of four different therapeutic regimens. J. Pediatr. Hematol. Oncol. 20:1998;583-586.
26. Raketien N., Raketien M.L., Nadkarmi M. Studies on the diabetogenic action of Streptozotocin. Cancer Chemother. Rep. 29:1963;91-98.
27. Junod A., Lambert A.E., Orci L., Pictet R., Gonet A.E., Renold A.E. Studies of the diabetogenic action of Streptozotocin. Proc. Soc. Exp. Biol. Med. 126:1967;201-205.
28. Weiss R.B. Streptozotocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat. Rep. 66:1982;427-438.
29. Tjälve H. Streptozotocin: distribution, metabolism and mechanisms of action. Uppsala J. Med. Sci. Suppl. 39:1983;145-157.
30. Bennett R.A., Pegg A.E. Alkylation of DNA in rat tissues following administration of Streptozotocin. Cancer Res. 41:1981;2786-2790.
31. 32P -labeling test for DNA damage Proc. Natl. Acad. Sci. U.S.A. 78:1981;6126-6129.
32. 6-methylguanine-DNA transmethylase from rat liver. J. Biol. Chem. 258:1983;2327-2333.
33. 6-methylguanine in human cell killing, sister chromatid exchange induction and mutagenesis: a review. J. Cell Sci. 6(Suppl.):1987;333-353.
34. G.P. Margison, P.J. O'Connor, Biological consequences of reactions with DNA: role of specific lesions, in: C.S. Cooper, P.L. Grover (Eds.), Handbook of Experimental Pharmacology 94/1, Springer, Berlin, 1990, pp. 547-571.
35. 6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid Res. Mol. Biol. 51:1995;167-223.
36. Capucci M.S., Hoffmann M.E., De Groot A., Natarajan A.T. Streptozotocin-induced toxicity in CHO-9 and V79 cells. Environ. Mol. Mutagen. 26:1995;72-78.
37. Saffhill R., Margison G.P., O'Connor P.J. Mechanisms of carcinogenesis induced by alkylating agents. Biochim. Biophys. Acta. 823:1985;111-145.
38. Loeb L.A. Apurinic sites as mutagenic intermediates. Cell. 40:1985;483-484.
39. Erickson L.C., Bradley M.O., Kohn K.W. Measurements of DNA damage in Chinese hamster cells treated with equitoxic and equimutagenic doses of nitrosoureas. Cancer Res. 38:1978;3379-3384.
40. Petzold G.L., Swenberg J.A. Detection of DNA damage induced in vivo following exposure of rats to carcinogens. Cancer Res. 38:1978;1589-1594.
41. Yamamoto H., Uchigata Y., Okamoto H. Streptozotocin and alloxan induced DNA strand breaks and poly(ADP-ribose)synthetase in pancreatic islets. Nature. 294:1981;284-286.
42. H. Okamoto, H. Yarnamoto, Y. Uchigata, Protection by superoxide dismutase, catalase and poly(ADP-ribose)synthetase inhibitors against alloxan- and Streptozotocin-induced islet DNA strand breaks and against proinsulin synthesis inhibition, in: K.G. Alberti, T. Ogada, J.A.A. Alouch, E.N. Mngola (Eds.), Proceedings of 11th Congress International Diabetes Federation, Excerpta Medica, Amsterdam, 1982, p. 13.
43. Uchigata Y., Yamamoto H., Kavamura A., Okamoto H. Protection by superoxide dismutase, catalase, and poly(ADP-ribose)synthetase inhibitors against alloxan- and Streptozotocin-induced islet DNA strand breaks and against the inhibition of proinsulin synthesis. J. Biol. Chem. 257:1982;6084.
44. LeDoux S.P., Woodley S.E., Patton N.J., Wilson G.L. Mechanisms of nitrosourea-induced β-cell damage. Alterations in DNA. Diabetes. 35:1986;866-872.
45. Brambilla G., Carlo P., Finollo R., Sciaba L. Dose-response curves for liver DNA fragmentation induced in rats by 16 N-nitroso compounds as measured by viscometric and alkaline elution analyses. Cancer Res. 47:1987;3485-3491.
46. Hartley J.A., Gibson N.W. DNA damage and cytotoxicity of 2-chloroethyl (methyllsulfonyl) methanesulfonate (NSC 338947) produced in human colon carcinoma cells with methylating agent pretreatment. Cancer Res. 46:1986;3871-3875.
47. + phenotype. Cancer Res. 46:1986;4995-4998.
48. Mossman B.T., Ireland C.M., Filipak M., LeDoux S., Wilson G.L. Comparative interactions of Streptozotocin and chlorozotocin with DNA of an insulin-secreting cell line (RINr). Diabetologia. 29:1986;186-191.
49. Pettepher C.C., LeDoux S.P., Bohr V.A., Wilson G.L. Repair of alkali-labile sites within the mitochondrial DNA of RINr 38 cells after exposure to the nitrosourea Streptozotocin. J. Biol. Chem. 266:1991;3113-3117.
50. Fram R.J., Mack S.L., George M., Marinus M.G. DNA repair mechanisms affecting cytotoxicity by Streptozotocin in E. coli. Mutat. Res. 218:1989;125-133.
51. Schmezer P., Eckert C., Liegibel U.M. Tissue-specific induction of mutations by Streptozotocin in vivo. Mutat. Res. 307:1994;495-499.
52. Kraynak A.R., Storer R.D., Jensen R.D., Kloss M.W., Soper K.A., Clair J.H., DeLuca J.G., Nichols W.W., Eydelloth R.S. Extent and persistence of Streptozotocin-induced DNA damage and cell proliferation in rat kidney as determined by in vivo alkaline elution and BrdUrd labeling assays. Toxicol. Appl. Pharmacol. 135:1995;279-286.
53. Murata M., Takahashi A., Saito I., Kawanishi S. Site-specific DNA methylation and apoptosis: induction by diabetogenic Streptozotocin. Biochem. Pharmacol. 57:1999;881-887.
54. Tyson C.K., Mirsalis J.C. Measurement of unscheduled DNA synthesis in rat kidney cells following in vivo treatment with genotoxic agents. Environ. Mutagen. 7:1985;889-899.
55. Shepherd J., Tsao M.S., Duguid W.P. Genotoxicity of pancreatic chemical carcinogens to propagable cultured normal pancreatic epithelial cells. Exp. Mol. Pathol. 53:1990;203-210.
56. Eizirik D.L., Bjorklund A., Cagliero E. Genotoxic agents increase expression of growth arrest and DNA damage - inducible genes gadd 153 and gadd 45 in rat pancreatic islets. Diabetes. 42:1993;738-745.
57. Sandler S., Swenne I. Streptozotocin, but not alloxan, induces DNA repair synthesis in mouse pancreatic islets in vitro. Diabetologia. 25:1983;444-447.
58. Sandler S., Swenne I. DNA repair synthesis in the pancreatic islets of Streptozotocin-treated mice. Diabetes Res. 2:1985;255-258.
59. Sandler S., Swenne I. Effects of Streptozotocin exposure in vitro on the replication and repair of DNA in fetal rat pancreatic islet cells. Pancreas. 4:1989;53-58.
60. Morgan N.G., Cable H.C., Newcombe N.R., Williams G.T. Treatment of cultured pancreatic β cells with Streptozotocin induces cell death by apoptosis. Biosci. Rep. 14:1994;243-250.
61. Saini K.S., Thompson C., Winterford C.M., Walker N.I., Cameron D.P. Streptozotocin at low doses induces apoptosis and at high doses causes necrosis in a murine pancreatic β-cell line, INS-1. Biochem. Mol. Biol. Int. 39:1996;1229-1236.
62. Harel A., Bloch O., Vardi P., Bloch K. Sensitivity of HaCat keratinocytes to diabetogenic toxins. Biochem. Pharmacol. 63:2002;171-178.
63. - radical generation by the xanthine oxidase system of pancreatic β cells. FEBS Lett. 239:1988;295-298.
64. Kawada J. New hypotheses for the mechanisms of Streptozotocin and alloxan inducing diabetes mellitus. Yakugaku Zasshi. 112:1992;773-791.
65. 2 as mediator for DNA fragmentation. Diabetes. 40:1991;1141-1145.
66. Ohkuwa T., Sato Y., Naoi M. Hydroxyl radical formation in diabetic rats induced by Streptozotocin. Life Sci. 56:1995;1789-1798.
67. Bedoya F.J., Solano F., Lucas M. N-monomethyl-arginine and nicotinamide prevent Streptozotocin-induced double strand DNA break formation in pancreatic rat islets. Experientia. 52:1996;344-547.
68. Kroncke K.D., Fehsel K., Sommer A., Rodriguez M.L., Kolb-Bachofen V. Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage. Biol. Chem. Hoppe Seyler. 376:1995;179-185.
69. Chen H., Carlson E.C., Pellet L., Moritz J.T., Epstein P.N. Overexpression of metallothionein in pancreatic β cell reduces Streptozotocin-induced DNA damage and diabetes. Diabetes. 50:2001;2040-2046.
70. Gandy S.E., Buse M.G., Crouch R.K. Protective role of superoxide dismutase against diabetogenic drugs. Clin. Res. 30:1982;392a.
71. Robbins M.J., Sharp R.A., Slonim A.E., Burr I.M. Protection against Streptozotocin-induced diabetes by superoxide dismutase. Diabetologia. 18:1980;55.
72. Gandy S.E., Buse M.G., Sorenson J.R.J., Crouch R.K. Attenuation of Streptozotocin diabetes with superoxide dismutase-1ike copper (nX3,5-diisopropylsalicylate) in the rat. Diabetologia. 24:1983;437.
73. Sandler S., Andersson A. The partial protection effect of the hydroxyl radical scavenger dimethylurea on Streptozotocin-induced diabetes in vivo and in vitro. Diabetologia. 23:1982;374.
74. Slonim A.E., Surber M.E., Page D.E., Sharp R.A., Burr I.M. Modification of chernically induced diabetes in rats by Vitamin E: supplementation minimizes and depletion enhances development of diabetes. J. Clin. Invest. 71:1983;1282.
75. B.K. Bhuyan, Action of Streptozotocin, an antileukemic antibiotic, on L1210 cells, in: P. Farnes (Ed.), In Vitro Vol. 4, Baltimore, The Williams and Wilkins Co., 1969, p. 154.
76. Kelly F., Legator M. The effects of N-methyl-N-nitro-N-nitrosoguanidine and Streptozotocin on mammalian cell cultures. Mutat. Res. 12:1971;183-190.
77. Capucci M.S., Hoffmann M.E., Zdzienicka M.Z., Natarajan A.T. Streptozotocin-induced chromosomal aberrations, SCEs and mutations in CHO-9 parental cells and in EM-C11 mutant cell line. Mutat. Res. 326:1995c;227-234.
78. Bolzán A.D., Bianchi N.O., Bianchi M.S. Effects of antioxidants on Streptozotocin-induced clastogenesis in mammalian and insect cells. Mutat. Res. 418:1998;35-42.
79. Bolzán A.D., González M.C., Bianchi M.S. The effect of 1,10-phenanthroline on the chromosome damage and sister-chromatid exchanges induced by Streptozotocin in mammalian and insect cells. Mutat. Res. 447:2000;221-226.
80. Bolzán A.D., Bianchi M.S. Chromosomal response of human lymphocytes to Streptozotocin. Mutat. Res. 503:2002;63-68.
81. Bhuyan B.K. The action of Streptozotocin on mammalian cells. Cancer Res. 30:1970;2017-2023.
82. Kaina B. Correction of alkylation hypersensitivity of CHO-W27-1 by transfection with human DNA. Carcinogenesis. 11:1987;1209-1212.
83. 6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair comprornised cells: facts and models. Mutat. Res. 381:1997;227-241.
84. 6-alkylguanine and N-alkyIpurines to the formation of sister chromatid exchanges, chromosomal aberrations, and gene mutations: new insights gained from studies of genetically engineered mammalian cell lines. Environ. Mol. Mutagen. 22:1993;283-292.
85. A.D. Bolzán, M.S. Bianchi, Clastogenic Effects of Streptozotocin on Human Colon Cancer Cell Lines, submitted for publication.
86. Liegibel U., Tinwell H., Callander R.D., Schmezer P., Ashby J. Clastogenicity to the mouse bone marrow of the mouse germ cell genotoxin Streptozotocin. Mutagenesis. 7:1992;471-474.
87. 6-alkylating agent induced clastogenicity by enhanced DNA repair capacity of bone marrow cells. Mutat. Res. 416:1998;1-10.
88. Galloway S.M., Greenwood S.K., Hill R.B., Bradt C.I., Bean C.L. A role for mismatch repair in production of chromosome aberrations by methylating agents in human cells. Mutat. Res. 346:1995;231-245.
89. Zlotogorski C., Erickson L.C. Pretreatrnent of normal human fibroblasts and human colon carcinoma cells with MNNG allows chloroethylnitrosourea to produce DNA interstrand crosslinks not observed in cells treated with chloroethylnitrosourea alone. Carcinogenesis. 4:1983;759-763.
90. Zeller W.J., Berger M.R., Henne T., Weber E. More than additive toxicity of the combination of 1-methyl-1-nitrosourea plus 1,3-bis(2-chloroethyl)-I-nitrosourea in the rat. Cancer Res. 46:1986;1714-1716.
91. Futscher B.W., Micetich K.C., Barnes D.M., Fisher R.I., Erickson L.C. Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells. Cancer Commun. 1:1989;65-73.
92. 6-methylguanine DNA methyltransferase activity and mRNA levels in HT-29 cells in vitro. Cancer Res. 51:1991;1581-1585.
93. Tokuda K. Effect of pretreatment with N-methyl-N-nitrosourea or Streptozotocin on the cytotoxicity and the induction of sister chromatid exchanges in human and rodent brain tumor cells treated with chloroethylnitrosourea. Hokkaido Igaku Zasshi. 67:1992;462-474.
94. 6-alkylguanine-DNA alkyltransferase by Streptozotocin in vivo. Cancer Res. 49:1989;3134-3138.
95. Micetich K.C., Futscher B., Koch D., Fisher R.I., Erickson L.C. Phase I study of Streptozotocin- and carmustine-sequenced administration in patients with advanced cancer. J. Natl. Cancer Inst. 84:1992;256-260.
96. 6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using Streptozotocin: a phase I trial. Cancer Res. 52:1992;2456-2459.
97. 6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers. J. Clin. Oncol. 13:1995;2301-2308.
98. 6-alkylguanine alkyltransferase. Clin. Cancer Res. 2:1996;1129-1134.
99. 6-methylguanine-DNA-methyltransferase activity and are hypermutable by alkylating agents. Carcinogenesis (London). 8:1987;1109-1113.
100. Samson L., Linn S. Alkylation repair and the induction of cell death and sister chromatid exchange in human cells. Carcinogenesis (London). 8:1987;227-230.
101. Aquilina G., Zijno A., Moscufo N., Dogliotti N.E., Bignami M. Tolerance to methylniytosourea-induced DNA damage is associated with 6-thioguanine resístanse in CHO cells. Carcinogenesis. 10:1989;1219-1223.
102. 6-alkylguanine, incorporated 6-thioguanine and UV photoproducts. Mutat. Res. 274:1992;225-235.
103. Ishida R., Utsumi K.R. Differences in induction of sister chromatid exchange in MNNG-resistant HeLa S3-Mer-cell lines. Carcinogenesis. 11:1990;1209-1212.
104. Mello-Filho A., Meneghini R. Protection of mammalian cells by o-phenanthroline from lethal and DNA-damaging effects produced by active oxygen species. Biochim. Biophys. Acta. 847:1985;82-89.
105. Eizirik D.L., de Lucio M.A., Boschero A.C., Hoffmann M.E. 1,10 Phenanthroline, a metal chelator, protects against alloxan- but not Streptozotocin-induced diabetes. J. Free Radic. Biol. Med. 2:1986;189-192.
106. Kaina B. Critical steps in alkylation-induced aberration formation. Mutat. Res. 404:1998;119-124.
107. Kolbye S.M., Legator M.S. Mutagenic activity of Streptozotocin. Mutat. Res. 6:1968;387-389.
108. Ficsor G., Muthiani E. A microbial assay for detecting chemical mutagens in tissue homogenates. Mutat. Res. 12:1971;335-337.
109. McCann J., Choi E., Yamasaki E., Ames B.N. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc. Natl. Acad. Sci. U.S.A. 72:1975;5135-5139.
110. Zimmer D.M., Bhuyan B.K. Mutagenicity of Streptozotocin and several other nitrosourea compounds in Salmonella typhimurium. Mutat. Res. 40:1976;281-288.
111. Ficsor G., Bordas S., Stewart S.J. Mutagenicity testing of benomyl, methyl-2-benzimidazole carbamate, Streptozotocin and N-methyl-N′-nitro-N-nitrosoguanidine in Salmonella typhimurium in vitro and in rodent host-mediated assays. Mutat. Res. 51:1978;151-164.
112. Franza B.R. Jr., Oeschger N.S., Oeschger M.P., Schein P.S. Mutagenic activity of nitrosourea antitumor agents. J. Natl. Cancer Inst. 65:1980;149-154.
113. Fram R.J., Sullivan J., Marinus M.G. Mutagenesis and repair of DNA damage caused by nitrogen mustard, N,N′-bis(2-chloroethyl)-N-nitrosourea (BCNU), Streptozotocin and mitomycin C in E. coli. Mutat. Res. 66:1986;299-342.
114. Marczewska J., Koziorowska J. Comparison of the induction of SOS repair in Escherichia coli PQ37 and PQ243 by antineoplastic agents. Acta Pol. Pharm. 54:1997;35-41.
115. Lengeler J. Characterisation of mutants of Escherichia coli K12, selected by resistance to Streptozotocin. Mol. Gen. Genet. 179:1980;49-54.
116. Mack S.L., Fram R.J., Marinus M.G. Sequence specificity of Streptozotocin-induced mutations. Nucleic Acids Res. 16:1988;9811-9820.
117. Gabridge M.G., Denunzio A., Legator M.S. Microbial mutagenicity of Streptozotocin in animal-mediated assays. Nature. 221:1969;68-70.
118. Bhuyan B.K., Peterson A.R., Heidelberger C. Cytotoxicity, mutations and DNA damage produced in Chinese hamster cells treated with Streptozotocin, its analogs, and N-methyl-N′-nitro-N-nitrosoguanidine. Chem. Biol. Interact. 13:1976;173-179.
119. Browning L.S. Mutagenicity of various chemicals and their metabolites in Drosophila. Genetics. 74:1973;33. [abstract].
120. Rodríguez-Arnaiz R., Aranda J.H. Metabolic activation of four drugs in the eye mosaic assay measuring principally mitotic recombination in Drosophila melanogaster: differences in strain susceptibility and route of exposure. Mutat. Res. 305:1994;157-163.
121. Arison R.N., Feudale E.L. Induction of renal tumour by Streptozotocin in rats. Nature. 214:1967;1254-1255.
122. Rakieten N., Gordon B.S., Cooney D.A., Davis R.D., Schein P.S. Renal tumorigenic action of Streptozotocin in rats. Cancer Chemother. Rep. 52:1968;563-567.
123. Rakeiten N., Gordon B.S., Beaty A., Cooney D.A., Davis R.D., Schein P.S. Pancreatic islet cell tumors produced by the combined action of Streptozotocin and nicotinamide. Proc. Soc. Exp. Biol. Med. 137:1971;280-283.
124. Rakieten N., Gordon B.S., Beaty A., Cooney D.A., Schein P.S. Modification of renal tumorigenic effect of Streptozotocin by nicotinarnide: spontaneous reversibiJity of Streptozotocin diabetes. Proc. Soc. Exp. Biol. Med. 151:1976;356-361.
125. Iwase M., Nunoi K., Sadoshima S., Kikuchi M., Fujishima M. Liver, kidney and is let cell tumors in spontaneously hypertensive and normotensive rats treated with Streptozotocin. Tohoku J. Exp. Med. 159:1989;83-90.
126. Sibay T.M., Hayes J.A. Potential carcinogenic effect of Streptozotocin. Lancet. 2:1969;912.
127. Weisburger J.H., Griswold D.P., Prejean J.D., Casey A.E., Wood H.B., Weisburger E.K. The carcinogenic properties of some of the principal drugs used in clinical cancer chemotherapy. Recent Results Cancer Res. 52:1975;1-17.
128. Berman L.D., Hayes J.A., Sibay T.M. Effect of Streptozotocin in the Chinese hamster (Cricetulus griseus). J. Natl. Cancer Inst. 51:1973;1287-1294.
129. Robbiano L., Mereto E., Corbu C., Brambilla G. DNA damage induced by seven N-nitroso compounds in primary cultures of human and rat kidney cells. Mutat. Res. 368:1996;41-47.
130. Shepherd J.G., Chen J.R., Tsao M.S., Duguid W.P. Neoplastic transformation of propagable cultured rat pancreatic duct epithelial cells by azaserine and Streptozotocin. Carcinogenesis. 14:1993;1027-1033.
131. Reddi A.S., Jyothirmayi G.N., Halka K., Khan M.Y. Potentiation of renal tumorigenicity by cyclosporin A in Streptozotocin diabetic rats. Cancer Lett. 56:1991;109-115.
132. Konishi N., Diwan B.A., Ward J.M. Amelioration of sodium barbital-induced nephropathy and regenerative tubular hyperplasia after a single injection of Streptozotocin does not abolish the renal tumor promoting effect of barbital sodium in male F344/NCr rats. Carcinogenesis. 11:1990;2149-2156.
133. Kazumi T., Yoshino G., Fujii S., Baba S. Tumorigenic action of Streptozotocin on the pancreas and kidney in male Wistar rats. Cancer Res. 38:1978;2144-2147.
134. Okamoto H., Yamamoto H. DNA strand breaks and poly(ADP-ribose) synthetase activation in pancreatic islets - a new aspect to development of insulin-dependent diabetes and pancreatic β-cell tumors. Princess Takamatsu Symp. 13:1983;297-308.
135. International Agency for Research on Cancer (IARC). Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans no. 17: Some N-Nitroso Compounds, Streptozotocin, 1978, pp. 337-345.
136. International Agency for Research on Cancer (IARC). Monographs, (Suppl. 7) 1987, p. 72.